MultiVu Video Feed: Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA

Monday, June 9, 2008 General News J E 4
ADDITIONAL RESOURCES: Video, hard copy requests, downloadable MPEG2,contact information and more available at


At the 68th Scientific Sessions of the American Diabetes Association inSan Francisco, CA, several studies were presented evaluating the impact ofblood sugar control to reduce diabetes-related complications in patients.

VADT (Veterans Affairs Diabetes Trial), a large, long-term and independentoutcomes study, evaluated whether intensive versus standard blood sugarcontrol can reduce the incidence of major cardiovascular (CV) eventsassociated with diabetes including heart attack, congestive heart failure andCV death.

According to news announced by the ADA, AVANDIA(R) (rosiglitazone maleate)was used in a majority of patients in the study and was not associated withincreased deaths. These data are consistent with results from other long-termstudies with AVANDIA.

The primary result of VADT did not show that intensive blood sugar control(HbA1c levels below 7%) had a statistically significant effect on reducingmajor CV events associated with diabetes. However, it was found that therewas a favorable trend in reducing all CV events, except CV death, among thepatients in the intensive arm. While the VADT did not meet its primaryendpoint, it is critical that these results do not detract from what isalready known about the benefits of long-term blood sugar control on otherserious and potentially life-threatening complications of diabetes, such askidney failure, blindness and amputation. VADT is an independent studysponsored by the Department of Veterans Affairs.NEW YORK, June 9 /PRNewswire/ -- SATELLITE FEED: Monday, June 9th, 2008 1:00 PM - 1:15 PM ET Galaxy 26 Transponder 24 C-Band Downlink Freq: 4180 H NEWS: LARGE, LONG-TERM VETERANS AFFAIRS DIABETES TRIAL (VADT) REVEALS IMPORTANT CARDIOVASCULAR SAFETY NEWS ON AVANDIA FORMAT: B-roll and Sound bites

SOURCE GlaxoSmithKline


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
PR Newswire Broadcast Minute for Monday, June 9
Paul Capital Healthcare Leads Panel on Strategic F...